John leads Amgens Biologic Discovery function responsible for identifying large molecule therapeutic candidates in collaboration with all Amgen Therapeutic Areas, including the discovery of fully human antibody therapeutics using the companys proprietary XenoMouse platform technology. John joined Amgen in 1992,and is currently based at the Amgen South San Francisco site, leading research teams in numerous Amgen locations. In 2010, John added the site leadership role for Amgens Burnaby, British Columbia research facility, managing the companys significant protein science resources in Canada, and overseeing site administration.
John holds a Bachelor of Science in Zoology from the University of Montana and earned his Ph.D. in the Department of Microbiology at the University of Arizona. He completed his postdoctoral training at the University of Utahs Department of Cellular, Viral, and Molecular Biology working on the molecular biology of bacterial thermotolerance.